PharVision Advisers’s ModivCare MODV Stock Holding History

PharVision Advisers’s Portfolio MODV Stock Details MODV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-58,456	Closed	-$692K	–	431
2024 Q4	$692K	Buy	+58,456	New	+$925K	0.59%	17

Other funds holding MODV

CCM

Coliseum Capital Management Rowayton, Connecticut $1.22B AUM 18.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PharVision Advisers's MODV Position: Q1 2025 in Review

PharVision Advisers sold out of ModivCare (MODV) in Q1 2025, closing a stake of 58,456 shares — an estimated $692K sold.

PharVision Advisers first reported a position in MODV in Q4 2024 and held it in 1 quarter. The position peaked at $692K in Q4 2024. 91 funds tracked by Wall St. Rank hold MODV as of Q1 2025.

PharVision Advisers reported no remaining ModivCare position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 58,456 ModivCare shares in Q1 2025, an estimated $692K.
PharVision Advisers first reported a position in ModivCare in Q4 2024 and held it in 1 quarter.
PharVision Advisers's ModivCare position peaked at $692K in Q4 2024.
91 funds tracked by Wall St. Rank held ModivCare as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.